Pinetree Therapeutics Raises $47 Million in Oversubscribed Series B to Advance Next-Generation Protein Degraders in Oncology
1 month ago
CAMBRIDGE, Mass., Oct. 28, 2025 /PRNewswire/ -- Pinetree Therapeutics, a preclinical-stage biotechnology company pioneering targeted protein degraders for drug-resistant cancers, announced the successful closing of an oversubscribed $47 million Series…